Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
van Krieken, JH; Jung, A; Kirchner, T; Carneiro, F; Seruca, R; Bosman, FT; Quirke, P; Fléjou, JF; Plato Hansen, T; de Hertogh, G; Jares, P; Langner, C; Hoefler, G; Ligtenberg, M; Tiniakos, D; Tejpar, S; Bevilacqua, G; Ensari, A.
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
Virchows Arch. 2008; 453(5): 417-431.
Doi: 10.1007/s00428-008-0665-y
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Höfler Gerald
- Langner Cord
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with colorectal carcinoma. However, these therapies are effective only in a subset of patients. Activating mutations in the KRAS gene are found in 30-40% of colorectal tumors and are associated with poor response to anti-EGFR therapies. Thus, KRAS mutation status can predict which patient may or may not benefit from anti-EGFR therapy. Although many diagnostic tools have been developed for KRAS mutation analysis, validated methods and standardized testing procedures are lacking. This poses a challenge for the optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Here we review the molecular basis of EGFR-targeted therapies and the resistance to treatment conferred by KRAS mutations. We also present guideline recommendations and a proposal for a European quality assurance program to help ensure accuracy and proficiency in KRAS mutation testing across the European Union.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies - therapeutic use
- Colorectal Neoplasms - drug therapy
- Europe -
- Genetic Screening -
- Humans -
- Point Mutation - genetics
- Predictive Value of Tests -
- Proto-Oncogene Proteins - genetics
- Quality Assurance, Health Care -
- Receptor, Epidermal Growth Factor - antagonists and inhibitors
- ras Proteins - genetics
- Find related publications in this database (Keywords)
- Colorectal carcinoma
- Anti-EGFR therapy
- KRAS mutation testing
- Practice guidelines
- Quality assurance